AG-490 (Tyrphostin B42)是一种EGFR抑制剂，在无细胞试验中IC50为0.1μM，作用于EGFR比作用于ErbB2选择性高135倍，对JAK2也有抑制作用，对Lck，Lyn，Btk，Syk和Src没有抑制活性。

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

AG 490; Tyrphostin AG 490; AG490; Zinc02557947;AG-490 (Tyrphostin B42)

yellow solid

DMSO：58 mg/mL (197.07 mM)

Ethanol：6 mg/mL (20.38 mM)

EGFR

AG490 significantly inhibits the development of type 1 diabetes (T1D) (p = 0.02, p = 0.005; at two different time points). Monotherapy of newly diagnosed diabetic NOD mice with AG490 (1 mg/mouse) markedly results in disease remission in treated animals (n=23) in comparision to the JPolute inability (0%; 0/10, p=0.003, Log-rank test) of DMSO and sustained eugluycemia is maintained for several months following drug withdrawal. AG490 (1-10 µg) significantly attenuates ʎ-carrageenan-induced thermal hyperalgesia in a dose-dependent manner. AG490 also reduces mechanical hyperalgesia.

[1] Gazit A, et al. J Med Chem, 1991, 34(6), 1896-1907.
[2] Meydan N, et al. Nature, 1996, 379(6566), 645-648.
[3] Nielsen M, et al. Proc Natl Acad Sci U S A, 1997, 94(13), 6764-6769.
[4] Kirken RA, et al. J Leukoc Biol, 1999, 65(6), 891-899.
[5] Sun X, et al. Blood, 2001, 97(7), 2008-2015.
[6] Burdelya L, et al. Mol Cancer Ther, 2002, 1(11), 893-899.
[7] Samanta AK, et al. Cancer Res, 2006, 66(13), 6468-6472.
[8] Abe M, et al. Int Immunopharmacol, 2009, 9(7-8), 870-877.